Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laura Heath

Podiatrist, Foot & Ankle Surgery Phoenix, AZ Doctor of Podiatric Medicine

NPI 1447509583 CMS profile 1144989

3330 N 2Nd St Ste 100, Phoenix, AZ 85012

Open in the dashboard

General payments

$8,101

130 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Heath of Phoenix, AZ is reported in the CMS Open Payments database as having received $8,101 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $347 9
2024 General $347 9
2023 General $471 13
2022 General $2,187 28
2021 General $2,565 36
2020 General $592 16
2019 General $1,592 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Heath
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Laura Heath were reported at $347. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Laura Heath Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $1,592 $389 $118–$1,406 $163
2020 $592 $191 $62–$691 $114
2021 $2,565 $329 $104–$1,341 $132
2022 $2,187 $419 $125–$1,611 $149
2023 $471 $377 $128–$1,164 $160
2024 $347 $394 $134–$1,168 $164
2025 $347 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $4,522 47 payments
  2. Novastep Inc. $1,721 12 payments
  3. Arthrosurface Incorporated $347 3 payments
  4. Nevro Corp. $252 6 payments
  5. Encore Medical, LP $182 1 payment
  6. Abbott Laboratories $132 5 payments
  7. Orthofix Medical, Inc. $125 18 payments
  8. Organogenesis Inc. $104 3 payments
  9. Medline Industries, Inc. $84 1 payment
  10. Wright Medical Technology, Inc. $79 4 payments
  11. Other $553 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,294 122 payments
  2. Travel and Lodging $2,807 8 payments
Products named General payments · program years 2019–2025
  1. PECA Bunion Correction System $1,579 10 payments
  2. PRIME SERIES $660 1 payment
  3. VARIAX $638 3 payments
  4. ALLOWRAP $470 3 payments
  5. HemiCAP MTP Resurfacing $347 3 payments
  6. ADAPT $311 4 payments
  7. SONICANCHOR $311 4 payments
  8. ORTHOLOC 2 LAPIFUSE $290 4 payments
  9. T2 $289 5 payments
  10. AUGMENT INJECTABLE $225 4 payments
  11. Other $3,372 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

451

Median for Podiatry: 160

Drug cost

$7,287

Median for Podiatry: $2,368

Branded share of claims

31.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 96 $2,805
Gabapentin Generic 85 $1,267
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 45 $674
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $578
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $482
Terbinafine Hcl Generic 24 $320
Ssd Silver Sulfadiazine Brand 22 $312
Diclofenac Sodium Generic 29 $276
Silver Sulfadiazine Generic 22 $267
Cephalexin Generic 28 $113

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$41,282

Medicare's payments for the services billed

Medicare patients

101

Average age 71

Services billed

706

53 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 56%
Arthritis 46%
Chronic kidney disease 35%
Ischemic heart disease 25%
Depression 22%
Heart failure 16%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record